The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also covers a severe form of the blistering and open-wound disorder known as recessive dystrophic epidermolysis bullosa, or RDEB. The FDA…
News
Recent Posts
- $1M matching gift supercharges the 9th annual Plunge for Elodie
- Long-term Dupilumab promotes itch relief across DEB subtypes
- High-frequency ultrasound helps doctors see beneath surface of EB skin
- Inmune Bio plans to seek approval of RDEB treatment in UK, US, and EU in 2026
- A Q&A with my son about life and EB ahead of his 17th birthday